Page 10 - Presentation
P. 10
177 Lu-PSMA-617: LuPSMA Trial
Single arm, single centre, phase 2 study
18
Screening: [⁶⁸Ga]-PSMA-11 PET/CT and F-FDG PET/CT
• High PSMA expression: standardised uptake value [SUV]
16% max of tumour 1·5 x SUV of liver
excluded • No discordant disease: excluded if sites of FDG-positive
based on PET disease without high PSMA expression
scan results
Treatment: 4 cycles every 6 weeks
• The administered radioactivity was adjusted from 6 GBq
• Activity was increased by 1 GBq if there were more
than 20 sites of disease, or decreased by 1 GBq if fewer
than ten sites
• Activity was increased by 0·5 GBq per factor if weight
was more than 90 kg or GFR was more than 90 mL per
min, and decreased by 0·5 GBq if weight was lower
than 70 kg or GFR was less than 60 mL per min
MS Hofman, et al. Lancet Oncol 2018; 19: 825–33
